NCT00418561View on ClinicalTrials.gov

Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 22, 2007

Primary Completion Date

March 27, 2008

Study Completion Date

March 27, 2008

Conditions
Metachromatic Leukodystrophy (MLD)
Interventions
BIOLOGICAL

rhASA - Dose Level 1

Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks

BIOLOGICAL

rhASA - Dose Level 2

Intravenous infusion 100 U/kg every other week for 26 weeks

BIOLOGICAL

rhASA - Dose Level 3

Intravenous infusion 200 U/kg every other week for 26 weeks

Trial Locations (1)

DK-2650

Rigshospitalet, Hvidovre

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT00418561 - Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) | Biotech Hunter | Biotech Hunter